Infinity Pharmaceuticals Inc.

Steven H. Holtzman , age 55, has served as our Chief Executive Officer and Chair of our board of directors since September 2006, and as our president from October 2007 to October 2008. Mr. Holtzman is also a co-founder of Old Infinity and served as its Chief Executive Officer and as Chair of its board of directors from inception in 2001 through completion of the reverse merger. Mr. Holtzman has also served as President of Old Infinity from July 2001 to February 2006. From 1994 to 2001, Mr. Holtzman served as Chief Business Officer of Millennium Pharmaceuticals, Inc., a publicly-traded pharmaceutical company. From 1996 to 2001, Mr. Holtzman served as a presidential appointee to the National Bioethics Advisory Commission, the principal advisory body to the President and Congress on ethical issues in the biomedical and life sciences. Prior to joining Millennium Pharmaceuticals, Inc., from 1986 to 1994, Mr. Holtzman was a founder and Executive Vice President of DNX Corporation, a publicly-traded biotechnology company. Mr. Holtzman is a director of Anadys Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company, and a trustee of the Berklee College of Music. Mr. Holtzman received a B.A. in Philosophy from Michigan State University and a B.Phil. in Philosophy from Oxford University, which he attended as a Rhodes Scholar.

David S. Grayzel, M.D., is Vice President, Clinical Development and Medical Affairs. Dr. Grayzel is currently responsible for leading Infinity's clinical research efforts and oversees both clinical development and clinical operations. Prior to Infinity, he was at Dyax Corp., a biopharmaceutical company focused on antibody and protein therapeutics. At Dyax, he was Director of Corporate Development and Business Operations, responsible for marketing and commercialization strategy for therapeutic products in the development pipeline, including late-stage clinical trials as well as business initiatives for in-licensing of targets, out-licensing of late-stage compounds, and co-development partnerships. Dr. Grayzel obtained his medical degree at Harvard Medical School and completed his internship and residency training in Internal Medicine at Massachusetts General Hospital. Prior to his medical training, Dr. Grayzel was a Curriculum Director at Stanford University Medical Center, creating their first case-based medical ethics curriculum. He holds a B.A. with honors from Stanford University.

Gerald E. Quirk, Esq., is Vice President and General Counsel. He is responsible for Infinity’s legal and compliance initiatives, as well as the company’s intellectual property portfolio. He has extensive experience representing biotechnology companies in connection with securities offerings and SEC compliance activities, mergers and acquisitions, licensing and other collaboration agreements, and product commercialization initiatives. Prior to joining Infinity, Mr. Quirk served in a number of progressively responsible legal and business development positions at Genzyme Corporation, having most recently been responsible for the provision of all non-patent legal services to Genzyme’s oncology, cardiovascular, and medical device businesses. Mr. Quirk began his career as an associate in the business law department and biotechnology practice group at Palmer & Dodge LLP, a Boston law firm. Mr. Quirk earned his J.D. from Northeastern University School of Law, an Ed.M. in Educational Administration from Harvard University, and a B.A. in Political Science from Swarthmore College.

Jeffrey K. Tong, Ph.D., is Vice President, Corporate and Product Development. Dr. Tong is responsible for leading Infinity's product development teams and corporate development efforts. Prior to joining Infinity, Dr. Tong was with the Palo Alto office of McKinsey & Company, where his work focused in healthcare with projects for leading biotechnology and pharmaceutical companies in areas of new business building, technology spinouts, and venture investing. Prior to McKinsey, Dr. Tong was a founding researcher of the Harvard Center for Genomics Research. Dr. Tong received his educational training at the interface of molecular biology, synthetic chemistry, and medicine. His previous research interest was in the area of histone deacetylase biology where he was involved with multiple teams in the identification and functional characterization of novel histone deacetylases and their macromolecular complexes. Dr. Tong holds A.B. and M.M.S. degrees from Harvard College and Harvard Medical School, respectively, as well as A.M. and Ph.D. degrees from Harvard University under the direction of Professor Stuart Schreiber.

John J. Keilty is Vice President, Information Technology and Informatics. Mr. Keilty is responsible for information systems, software development, structural biology, bioinformatics, and clinical informatics. Prior to joining Infinity, Mr. Keilty was an early member of Millennium Pharmaceuticals where he held various roles of increasing responsibility, including Senior Manager of Molecular Research Services with broad ownership for the creation, management, implementation and transfer of much of the company’s core genomic technologies. Many of the developed software applications, algorithms and laboratory procedures were transferred to Millennium’s corporate partners as part of larger business collaborations. Before Millennium, Mr. Keilty worked in the Howard Hughes lab of Michael Green at University of Massachusetts Medical Center, focusing on basic research in transcription and gene splicing. Mr. Keilty holds a B.A. in biology from Clark University.

Michael S. Curtis, Ph.D., is Vice President of Pharmaceutical Development with responsibility for manufacturing, formulation, and analytical characterization of Infinity's pre-clinical and clinical drug candidates. Prior to joining Infinity, Dr. Curtis was an Associate Director within the Pharmaceutical and Analytical Development group at Transkayotic Therapies (TKT, currently Shire) where he was responsible for analytical methods development and validation to support the registration of Elaprase® (idursulfase). Before TKT, Dr. Curtis was the Associate Director of Analytical Development at Syntonix Pharmaceuticals where he was involved with advancing the Transceptor® drug delivery technology and in particular its expansion as an oral delivery platform. Prior to Syntonix, he was a member of the Therapeutic Protein Research group at Genzyme working on the development and characterization of the enzyme replacement therapy Myozyme® (alglucosidase alfa). Dr. Curtis began his career at Bristol-Myers Squibb where he held positions of increasing responsibility working in small molecule and biologics development, most significantly on the manufacturing processes for Capoten® (captopril) and Taxol® (paclitaxel) and the early development of Orencia® (abatacept). Dr. Curtis received his B.S. in Biochemistry from the State University of New York College of Environmental Science and Forestry and his Ph.D. in Cell and Molecular Biology from Upstate Medical University.

Steven J. Kafka, Ph.D., is Vice President, Finance. Dr. Kafka oversees investor and public relations, financial planning and analysis, accounting, treasury, purchasing, and business operations. Dr. Kafka joined Infinity from Millennium Pharmaceuticals, where he was Senior Director, Finance. As leader of the Financial Planning and Analysis group at Millennium, he and his team were responsible for corporate business planning, financial management, and product portfolio strategy support. He also served as a member of the VELCADE® leadership team where he helped to establish and guide the product’s U.S. commercial strategy and operations and its global co-development strategy with partner Johnson & Johnson. Dr. Kafka worked for several years as a senior member of the life sciences practice of Strategic Decisions Group (SDG), a business strategy consulting firm, where he specialized in the pharmaceutical industry. His experience at SDG included leadership of portfolio integration efforts for the merger of two global pharmaceutical firms, establishment of portfolio strategy and ongoing management for the Japanese assets of a global biopharmaceutical firm, and product development strategy projects across a host of therapeutic areas.

Vito J. Palombella, Ph.D., is Vice President, Drug Discovery. Prior to joining Infinity, Dr. Palombella was at Syntonix Pharmaceuticals. At Syntonix he was Director of Molecular Biology and Protein Chemistry, responsible for improving and expanding its core Fc receptor-mediated drug delivery technology. Before joining Syntonix, Dr. Palombella was Senior Director of Cell and Molecular Biology at Millennium Pharmaceuticals, which he joined through its acquisition of LeukoSite (where he held the same title) in 1999. Prior to its acquisition by LeukoSite, Dr. Palombella held a number of positions at ProScript, Inc. (between 1994 and 1999). While at ProScript, LeukoSite, and Millennium, Dr. Palombella was involved in the discovery and development of VELCADE®, a proteasome inhibitor for cancer therapy. He also managed a number of additional projects, including research into NF-?B regulation. Dr. Palombella received a B.S. in Microbiology from Rutgers University and his M.S. and Ph.D. in Viral Oncology and Immunology from the New York University Medical Center. He was also a post-doctoral fellow at Harvard University in the laboratory of Dr. Tom Maniatis.

Frank Moss, Ph.D., is a co-founder of Infinity. Since 1998, Dr. Moss has been President of Strategic Software Ventures, a firm that nurtures enterprise software startup companies; since February 2006, Dr. Moss has served as Director of The Media Lab and Weisner Professor of Media Arts and Sciences at the Massachusetts Institute of Technology. From 1991 - 1996, Dr. Moss served as Chief Executive Officer and Chairman of Tivoli Systems, a private software company sold to IBM in 1996. Prior to joining Tivoli Systems, Dr. Moss held a variety of positions with Lotus Development, Stellar Computer, Apollo Computer, and IBM Research. Dr. Moss received a B.S. in Aerospace and Mechanical Sciences from Princeton University and an S.M. and Ph.D. in Aeronautics and Astronautics from the Massachusetts Institute of Technology.

Eric S. Lander, Ph.D., is a co-founder of Infinity. Dr. Lander has been a Professor and Associate Professor of Biology at the Massachusetts Institute of Technology since 1990 and a Professor of Systems Biology at Harvard Medical School since 2004. Dr. Lander has served as the founding Director of The Eli and Edythe L. Broad Institute, a biomedical research institute formed by MIT and Harvard University, since 2003 and as a member of the Whitehead Institute for Biomedical Research since 1989. From 1993 - 2003, Dr. Lander was the Director of the Whitehead/MIT Center for Genome Research. Dr. Lander received an A.B. in Mathematics from Princeton University and a D.Phil. in Mathematics from Oxford University, which he attended as a Rhodes Scholar.

Arnold J. Levine, Ph.D., is a Professor at The Cancer Institute of New Jersey, Robert Wood Johnson School of Medicine and a Professor at the Institute for Advanced Study. From 1998 - 2002, Dr. Levine was President of Rockefeller University. Prior to joining Rockefeller University, Dr. Levine was the Harry C. Weiss Professor in the Life Sciences and Chairman of the Department of Molecular Biology at Princeton University from 1984 - 1996. Dr. Levine also serves as a Director of Theravance, Inc. and Applera Corporation, publicly traded life science companies. Dr. Levine received a B.A. in Biology from Harpur College, State University of New York at Binghamton and a Ph.D. in Microbiology from the University of Pennsylvania.

Jeanette W. Kohlbrenner is Senior Director, Human Resources. She is responsible for Infinity’s human resource and organizational development functions. Ms. Kohlbrenner joined Infinity with over 15 years of experience in senior human resource roles with life science and medical device companies, ranging from start-up to fully commercial, global organizations. Prior to joining Infinity, Ms. Kohlbrenner was the Business Unit Director of Human Resources for Cambrex Biosciences, with responsibilities for pharmaceutical development and manufacturing locations in the United States. Before Cambrex, Ms. Kohlbrenner was at Syntonix Pharmaceuticals, where she was the Director of Human Resources and a key member of the senior team, working to build the company. Ms. Kohlbrenner also held human resource roles with Genetics Institute/Wyeth Pharmaceuticals, and Hewlett-Packard’s Medical Device business (now Philips Medical). Early in her career, Ms. Kohlbrenner was a compensation and performance management consultant with William Mercer, a global leader in human resource consulting. Ms. Kohlbrenner holds an M.B.A. from Babson College and a B.A. in Mathematics from Holy Cross.

Vicki L. Sato, Ph.D., Lead Outside Director and Chair of Infinity's Compensation Committee, is currently a professor at Harvard University. From 1992 - 2005, Dr. Sato held various positions with Vertex Pharmaceuticals, Inc., a publicly traded pharmaceutical company, most recently serving as President from 2000 - 2005. Prior to joining Vertex Pharmaceuticals, Inc., from 1984 - 1992, Dr. Sato held various positions with Biogen, Inc., a publicly traded biotechnology company, most recently serving as Vice President of Research and a member of the Scientific Advisory Board. Since 1993, Dr. Sato has served on the Board of Tutors, Department of Biochemistry and Molecular Biology at Harvard University, and also served as an Assistant Professor and Associate Professor in the Department of Biology at Harvard University from 1975 - 1983. Dr. Sato is a business advisor to Atlas Ventures, a venture capital firm, and other enterprises in the biotechnology and pharmaceutical industries. Dr. Sato serves as an overseer of the Isabella Stewart Gardner Museum and is a trustee of Jose Mateo’s Ballet Theatre. Dr. Sato serves as a director of Bristol-Myers Squibb Company and Alnylam Pharmaceuticals, Inc., publicly traded biopharmaceutical companies, Perkin-Elmer, Inc., a diversified company with businesses in the life and analytical sciences and optoelectronics, and Avila Therapeutics, a private biotechnology company. Dr. Sato received an A.B. in Biology from Radcliffe College and an M.A. and Ph.D. in Biology from Harvard University.

Anthony B. Evnin, Ph.D. , a director since October 2006, is a General Partner of Venrock, a venture capital firm, where he has been a Partner since 1975. He is currently a member of the Board of Directors of Icagen, Inc., Infinity Pharmaceuticals, Inc and Sunesis Pharmaceuticals, Inc., as well as being on the Board of Directors of a number of private companies. Dr. Evnin received an A.B. in Chemistry from Princeton University and a Ph.D. in Chemistry from the Massachusetts Institute of Technology.

Ian Smith joined Vertex in November 2001. Prior to joining Vertex, Mr. Smith served as a partner in the Life Science and Technology Practice Group of Ernst & Young LLP, an accounting firm, from 1999 to 2001. As Vertex’s CFO, Mr. Smith holds responsibility for a wide variety of core functions at Vertex, including Finance, Strategic Communications, Information Systems and Operations. Mr. Smith is also a member of the Executive Team at Vertex. Mr. Smith received a B.A. with honors in Accounting and Finance from Manchester Metropolitan University. Mr. Smith is a current member of the American Institute of Certified Public Accountants, the Institute of Chartered Accountants of England and Wales, and the Financial Executives Institute. Mr. Smith is a member of the Board of Directors of Acorda Therapeutics, Inc, Epix Pharmaceuticals, Inc. and TolerRx Inc. Additionally, he is a board member of the Massachusetts Biotechnology Council and is Chair of its Policy Committee.

Array

Array

Patrick Lee is a General Partner of Ares Life Sciences, an investment firm, since February 2009. Prior to Ares Life Sciences, Mr. Lee was a General Partner at Advent Venture Partners, a venture capital firm, where he was employed since 1999. Before Advent Venture Partners, from 1989 - 1999, Mr. Lee held various positions with Rhone-Poulenc Rorer in the U.S., and Rhone-Poulenc in Paris, France, where he was most recently Group Vice President for Mergers and Acquisitions. Prior to that he had been with Baxter International and Booz Allen Hamilton. Mr. Lee received a B.A. in Biology from Vassar College and an M.B.A. from the Stanford Graduate School of Business.